Expires

Severe/Resistant Hypercholesterolemia: New Agents Redefining Clinical Practice

Release Date: June 15, 2018
Expiration Date: June 15, 2019

 

 

 

PROGRAM OVERVIEW

Since hypercholesterolemia is a major driver of ASCVD, lipid-lowering therapies (mainly in combination with statins) are the primary approach to lower low-density lipoprotein cholesterol (LDL-C) and reduce CVD risk. Unfortunately, intensive statin therapy lowers CVD risk by only ~50%, leaving many patients at excessively high residual CVD risk. Recently approved PCSK9 inhibitors have been shown to produce robust LDL-C reduction (by ~60%) when co-administered with statins.

Severe/Resistant Hypercholesterolemia: New Agents Redefining Clinical Practice will help clinicians develop a refined understanding of residual CVD risk in hypercholesterolemic patients and allow them to adjust prescribing behavior to reduce risk as much as possible.

AGENDA

  • Welcome, Introductions
  • Guidelines, Trial Data, and Residual Risk
  • New and Emerging Treatment Options
  • Benefits and Limitations of Treatment Options
  • Concluding Remarks


FACULTY
 

Eliot A. Brinton

      
 Eliot A. Brinton, MD, FAHA, FNLA

 Past President, American Board of Clinical Lipidology
 President, Utah Lipid Center
 Salt Lake City, UT

 

Eliot A. Brinton, MD, FAHA, FNLA obtained his medical doctorate from the University of Utah, completed a residency in internal medicine at Duke University, and received fellowship training in metabolism, endocrinology, and nutrition at the University of Washington in Seattle. He has served as an Assistant Professor of Biochemical Genetics and Metabolism at the Rockefeller University in New York; as an associate professor of Medicine and Director of the Clinical Lipid Center at Wake Forest University; as Chief of Metabolism, Endocrinology, and Nutrition at the Carl T. Hayden Veterans Affairs Medical Center in Phoenix, AZ; as Associate Professor of Clinical Medicine at the University of Arizona College of Medicine; as Adjunct Professor of Cellular and Molecular Biology at Arizona State University; and as Co-director of the Phoenix Citywide Endocrinology and Metabolism Fellowship Program. Most recently, he served as Research Associate Professor and Director of the Metabolism Section of Cardiovascular Genetics at the University of Utah School of Medicine. Dr. Brinton is now serving as President of the Utah Lipid Center in Salt Lake City.

Dr Brinton was a founding and current board member of the National Lipid Association and is a Fellow of the NLA. He was Past President of the Pacific Lipid Association, a chapter of the NLA. He was also Past President and founding board member of the American Board of Clinical Lipidology. He is a Fellow of the American Heart Association, where he also served as Chair of the Clinical Lipidology Committee. He serves on two expert writing panels on lipoprotein treatment for the AHA, and one for the American Association of Clinical Endocrinology.

Dr. Brinton is widely published in the field of lipoprotein metabolism, having authored more than 100 original research articles and invited reviews in many prestigious journals, including Science, New England Journal of Medicine, JAMA, Circulation, and Journal of Clinical Investigation. He is Associate Editor of the Journal of Clinical Lipidology, Assistant Editor of the Journal of Obesity, and has served as Section Editor of Current Opinion in Atherosclerosis. He has held numerous leadership and advisory positions in scientific and governmental organizations and for the pharmaceutical industry. He is recipient of several honors, including the Robert I. Levy Award of the Lipoprotein Kinetics and Metabolism Society (shared with Jan L. Breslow, MD).

Dr. Brinton’s expertise in research, teaching, and clinical care covers not only adults, but also adolescents and children. His areas of special interest include the pathobiology and management of hypercholesterolemia, hypertriglyceridemia, and HDL deficiency; the pathogenesis and prevention of atherosclerosis; atheroprevention in postmenopausal estrogen deficiency; and the mechanisms and management of diabetes mellitus type 2, obesity, insulin resistance, metabolic syndrome, and related disorders.
 

Alan S. Brown, MD, FACC, FAHA, FNLA    Alan Brown, MD, FACC, FAHA, FNLA, FASPC
  
President, National Lipid Association
   Director, Division of Cardiology
   Advocate Heart Institute
   Advocate Lutheran General Hospital
   Co‐Director, Advocate Medical Group
   Park Ridge, IL

 

Alan S. Brown, MD, FACC, FAHA, FNLA has been the Director of the Prevention Center/Lipid Clinic for Midwest Heart Specialists since its inception in 1985. He is a practicing interventional cardiologist and preventative cardiologist. He was appointed Clinical Associate Professor of Medicine and Cardiology at Loyola from 1993 until the present. Dr. Brown is board-certified in internal medicine, cardiology, echocardiography, and clinical lipidology. He is the Director of the Division of Cardiology at the Advocate Heart Institute at Advocate Lutheran General Hospital in Park Ridge, IL, as well as Co-director of the Cardiology Service Line for Advocate Medical Group/Advocate Health Care.

Dr. Brown has served as Governor/President of the Illinois Chapter of the American College of Cardiology (ACC) and subsequently was elected Chairman of the Board of Governors for the ACC in 2004. He is a Fellow of the ACC, American Heart Association, and National Lipid Association, and has been a member of the ACC’s Prevention of Cardiovascular Disease Committee, Annual Scientific Program Committee, and Task Force for Appropriate Use Criteria. Dr. Brown served as a member of the ACC Board of Trustees from 2003-2006. He is President of the National Lipid Association and a member of the Board of Directors for the American Society for Preventative Cardiology.

Dr. Brown has authored numerous articles in the field of lipid management and prevention, as well as two book chapters. He is the host of Lipid Luminations, an internet radio show on Reach MD radio that focuses on lipid topics through interviews with national thought-leaders.

TARGET AUDIENCE

This activity is intended for clinical cardiologists, internists, and other healthcare professionals who provide direct care to patients impacted by ASCVD.

EDUCATIONAL OBJECTIVES

This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.                                                         

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Evaluate the relationship between residual hypercholesterolemia and residual CVD risk in high-risk patients
  • Define CVD risk elements to guide prescribing behavior
  • Differentiate the clinical properties of new and emerging pharmacologic approaches to reduce LDL-C and lower CVD risk
  • Analyze the potential strengths and weaknesses of new approaches to reduce CVD risk in combination with statins
  • Implement use of newer LDL-C lowering agents in combination with statins

ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

Boston University School of Medicine designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please email: cme@bu.edu.

DISCLOSURE/CONFLICT OF INTEREST STATEMENT

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Program Faculty Disclosures

The program faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Eliot A. Brinton, MD, FAHA, FNLA: Consultant: Akcea, Amarin, Amgen, Balchem, Kastle, Kowa, Merck, PTS Diagnostics, Regeneron, Sanofi; Speaker: Akcea, Amarin, Amgen, Boehringer Ingelheim, Kowa, Merck, Novo Nordisk, Regeneron, Sanofi

Alan Brown, MD, FACC, FAHA, FNLA, FASPC: Speaker: Amgen, Kowa, Regeneron, Sanofi; Advisory Board/Consultant: Akcea, Amgen, Kowa, Regeneron

Michael D. Klein, MD: CME Course Director, has no relevant financial relationships to disclose

Non-faculty Content Contributors Disclosures

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Barry Watkins, PhD; Chad Williamson, MS, MBA, CMPP; Blair St. Amand; Megan Boone; Natalie Sanfratello; Elizabeth Drury: Nothing to disclose

BOSTON UNIVERSITY SCHOOL OF MEDICINE DISCLAIMER

THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.                                                                                                                 

FDA DISCLOSURE                 

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

SYSTEM REQUIREMENTS

In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an internet browser capable of playing an HTML5 video.

INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT

There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test.  Participant is allowed to take the post-test multiple times.
 

Jointly provided by Boston University School of Medicine and Rockpointe

 

Boston University and Rockpointe

 

 

 

This activity is supported by educational funding donation provided by Amgen.

 

We Recommend